

CHAPTER Ph 1000 EMERGENCY CONTRACEPTION

PART Ph 1001 COLLABORATIVE PRACTICE FOR EMERGENCY CONTRACEPTION

Ph 1001.01 Collaborative Practice Authorized. Notwithstanding any other provisions of law, a licensed pharmacist who has completed the training required in Ph 1001.02 may initiate emergency contraception drug therapy in accordance with the provisions of Ph 1001.

Ph 1001.02 Education and Training.

(a) Any pharmacist initiating emergency contraception drug therapy shall complete a minimum of 0.2 CEU's, 2 didactic/live hours, of approved training and education prior to participating in the delivery of emergency contraception drug therapy.

(b) Programs for training and education, referenced in (a) above shall be:

(1) Accredited by the Accreditation Council for Pharmacy Education (ACPE); or

(2) Approved by the board of pharmacy according to Ph 403.01(b).

(c) Programs for training and education, as referenced above, shall include study materials and instruction in the following content areas:

(1) Mechanisms of action, contraindication, drug interaction, and monitoring of emergency contraception drug therapy;

(2) Current standards for prescribing emergency contraception drug therapy;

(3) Identifying indications for use of emergency contraception drug therapy;

(4) Interviewing patient to establish need for emergency contraception drug therapy;

(5) Counseling patient regarding the safety, efficacy and potential adverse effects of drug products for emergency contraception;

(6) Evaluating patient's medical profile for drug interaction;

(7) Referring patient follow-up care with primary healthcare provider;

(8) Informed consent;

(9) Record management;

(10) Management of adverse events, including identification, appropriate response, documentation and reporting;

(11) Management and response to negative public opinion; and

(12) Medical/forensic implications of sexual attack.

Ph 1001.03 Emergency Contraception Collaborative Agreement.

(a) Each arrangement between a licensed pharmacist and an authorized prescriber relating to the distribution to a patient of emergency contraception drugs shall be documented in a signed collaborative agreement in accordance with form Ph EC-1, which may be obtained from the office of the board identified in Ph 103.03.

(b) By signing the collaborative agreement, which may be modified according to the authorized practitioner, both the pharmacist and the authorized prescriber agree and acknowledge that:

(1) The licensed pharmacist shall provide the patient with drug information concerning dosage, potential adverse side effects, and follow-up contraceptive care;

(2) The collaborative agreement shall be effective for a period of 2 years unless rescinded in writing earlier by either the pharmacist or the authorized prescriber, with written notice to the other, or unless the board of pharmacy invalidates the agreement or changes the terms of the agreement;

(3) At the time the collaborative agreement expires or is rescinded, the licensed pharmacist shall not have authority to dispense emergency contraceptives until another collaborative agreement with an authorized prescriber is completed;

(4) Each drug therapy prescription authorized by the prescriber and dispensed by the pharmacist shall be documented in a patient profile; and

(5) No refills shall be permitted and the pharmacist shall not be authorized to provide a written, oral or electronic prescription enabling the patient to further obtain emergency contraception pursuant to the patient's immediate receipt of drug therapy.

(c) Additionally, the licensed pharmacist and the authorized prescriber shall include in the collaborative agreement the following:

(1) The name, address, phone number and signature of the licensed pharmacist;

(2) The name, address, phone number and signature of the authorized prescriber;

(3) A statement indicating the purpose of the collaborative agreement is to permit emergency contraception drug therapy and to ensure that the patient receives appropriate information from the licensed pharmacist regarding the drug therapy;

(4) The procedures to be followed by the licensed pharmacist when the patient requests drug therapy, including any applicable referrals;

(5) Any limitation agreed upon by both the licensed pharmacist and the authorized prescriber including, but not limited to, approved drugs that may not be dispensed to the patient;

(6) A statement that the label placed on the drug therapy product shall contain the names of both the pharmacist and the authorized prescriber of this agreement;

(7) An informed consent format to be used by the licensed pharmacist to inform the patient about the emergency contraception drug therapy; and

(8) A patient assessment format for each patient obtaining emergency contraception drug therapy shall be completed and signed by the licensed pharmacist on form Ph EC-3, which may be obtained from the office of the board identified in Ph 103.03.

(d) The informed consent referenced in (c)(7) above, shall be signed by both the licensed pharmacist and the patient on form Ph EC-2, which may be obtained from the office of the board identified in Ph 103.03.

Ph 1001.04 Informed Consent

(a) The licensed pharmacist shall provide the patient with an informed consent form, in accordance with form Ph EC-2, which may be obtained from the office of the board identified in Ph 103.03.

(b) The informed consent form shall include at least the following:

(1) The indications for use of emergency contraception;

(2) The mechanism of action of the medication;

(3) The appropriate method for taking the medication;

(4) The possible reactions after taking the medication; and

(5) The circumstances that may require follow-up with a physician.

(c) After the patient has read, and/or reviewed with the licensed pharmacist, the statements specified on the informed consent form, both the patient and the licensed pharmacist shall sign and date the form.

Ph 1001.05 Patient Assessment

(a) The licensed pharmacist shall perform a patient assessment, in accordance with form Ph EC-3, which may be obtained from the office of the board identified in Ph 103.03.

(b) The patient assessment form shall include at least the following;

- (1) Patient's name and address;
- (2) Patient's date of birth;
- (3) Personal information which requires the use of emergency contraception; and
- (4) Determination of any known allergies to medications/drugs.

Ph 1001.06 Provision of Standardized Fact Sheet Required.

(a) For each emergency contraception drug therapy initiated pursuant to this chapter, the pharmacist shall provide the recipient of the emergency contraceptive drug with a standardized fact sheet developed by the board that includes at least the following:

- (1) The indications for use of the drug;
- (2) The appropriate method for using the drug;
- (3) The need for medical follow-up and referral information; and
- (4) Information on sexual assault and referral information.

(b) A copy of the standardized fact sheet Ph EC-4 may be obtained from the office of the board identified in Ph 103.03.

Ph 1001.07 Records to be Kept. The following completed forms shall be maintained for 4 years at the dispensing pharmacy where emergency contraception drug therapy was provided:

(a) Collaborative Agreement (Ph EC-1), or a copy thereof, in effect during the time emergency contraception drug therapy was delivered to specific patients at that location;

(b) Informed Consent (Ph EC-2), patient specific forms; and

(c) Patient Assessment (Ph EC-3) forms for each patient.

Ph 1001.08 Confidentiality. Nothing in this chapter shall affect the provisions of law relating to maintaining the confidentiality of medical records.